• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Harrow Inc.

    3/17/25 5:12:19 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HROW alert in real time by email
    NT 10-K 1 formnt10-k.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 12b-25

     

     

     

    SEC File Number: 001-35814

    CUSIP Number: 415858109

     

    NOTIFICATION OF LATE FILING

     

    (Check One)  

    ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q

    ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

       
        For Period Ended: December 31, 2024
       
        ☐ Transition Report on Form 10-K
       
        ☐ Transition Report on Form 20-F
       
        ☐ Transition Report on Form 11-K
       
        ☐ Transition Report on Form 10-Q
       
        For the Transition Period Ended:

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

     

    PART I — REGISTRANT INFORMATION

     

    HARROW, INC.

    (Full Name of Registrant)

     

     

    (Former Name if Applicable)

     

    1A Burton Hills Blvd., Suite 200

    (Address of Principal Executive Office (Street and Number))

     

    Nashville, Tennessee 37215

    (City, State and Zip Code)

     

     

     

     

     

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

    (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III — NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Harrow, Inc. (the “Company”) is filing this Notification of Late Filing on Form 12b-25 with respect to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Form 10-K”).

     

    The Company could not file the Form 10-K within the prescribed period without unreasonable effort or expense. Although management has been working diligently to complete all of the required information for the Form 10-K, the Company requires additional time to perform certain accounting analyses, complete management’s evaluation of internal controls over financial reporting, and prepare certain disclosures.

     

    The Company anticipates that (i) the Form 10-K will not result in changes to the preliminary unaudited financial results for the full year and fourth quarter of 2024 announced in the Company’s press release dated March 17, 2025 furnished with a Current Report on Form 8-K dated March 17, 2025, and (ii) the Form 10-K will be filed as soon as practicable on or before the 15th calendar day following the prescribed due date.

     

     

     

     

    PART IV — OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification
             
      Andrew R. Boll   (615)   733-4730
      (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No
       
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
      ☒ Yes ☐ No
       
      If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
       
      See Attachment A hereto for preliminary unaudited financial results reported in the Company’s March 17, 2025 press release, which attachment is incorporated herein by reference.

     

     

     

     

    Harrow, Inc.

     

    (Name of Registrant as Specified in Charter)

     

    Has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date March 17, 2025 By:

    /s/ Andrew R. Boll

      Name: Andrew R. Boll
      Title: Chief Financial Officer

     

    INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

     

    ATTENTION

     

    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     

     

     

    Attachment A

     

    In its press release issued on March 17, 2025, included as Exhibit 99.1 to the Company’s Current Report on Form 8-K filed March 17, 2025 (the “Form 8-K”), the Company reported the following preliminary unaudited results with respect to its 2024 full fiscal year and fourth quarter.

     

        

    For the Three Months Ended
    December 31, 2024

        

    For the Year Ended
    December 31, 2024

     
    Revenues  $65 - $67 million   $198 - $200 million 
    Net Income (Loss)  $5 - $7 million   $(17) - $(19) million 
    Adjusted EBITDA (a non-GAAP measure)  $21 - $23 million   $39 - $41 million 

     

    Adjusted EBITDA

     

    The Company defines Adjusted EBITDA as net income (loss), excluding the effects of stock-based compensation and expenses, impairment of intangible assets, interest, taxes, depreciation, amortization, investment loss, net, and, if any and when specified, other non-recurring income or expense items. Management believes that the most directly comparable GAAP financial measure to Adjusted EBITDA is net income (loss). Adjusted EBITDA has limitations and should not be considered as an alternative to gross profit or net loss as a measure of operating performance or to net cash provided by (used in) operating, investing, or financing activities as a measure of ability to meet cash needs.

     

    The following is a reconciliation of Adjusted EBITDA, a non-GAAP measure, to the most comparable GAAP measure, net income (loss), for the three months and year ended December 31, 2024:

     

     

       For the Three Months
    Ended December 31, 2024
       For the Year Ended
    December 31, 2024
     
    GAAP net income (loss) range  $5,000,000 - 7,000,000   $ (17,000,000) – (19,000,000) 
    Stock-based compensation and expenses   4,794,000    17,619,000 
    Impairment of intangible assets   253,000    253,000 
    Interest expense, net   6,375,000    22,786,000 
    Income tax (benefit) expense   (514,000)   161,000 
    Depreciation   468,000    1,850,000 
    Amortization of intangible assets   4,075,000    11,783,000 
    Investment loss   -    3,171,000 
    Other expense, net   261,000    185,000 
    Adjusted EBITDA range   $20,712,000 - 22,712,000    $ 38,808,000 - 40,808,000  

     

     

     

    Get the next $HROW alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HROW

    DatePrice TargetRatingAnalyst
    2/6/2025$57.00Buy
    H.C. Wainwright
    12/4/2024$73.00 → $69.00Buy
    B. Riley Securities
    4/11/2024$24.00Buy
    Craig Hallum
    9/8/2022$17.00Buy
    B. Riley Securities
    10/14/2021$16.00Buy
    B. Riley Securities
    9/24/2021$15.00Buy
    Aegis Capital
    7/2/2021$14.25Buy
    Ladenburg Thalmann
    More analyst ratings

    $HROW
    Leadership Updates

    Live Leadership Updates

    See more
    • Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

      Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications. Dr. Shojaei most recently served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics, where he spearheaded the development of innovative therapies for neovascular retinal disorders. P

      1/7/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial

      Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saharek, Harrow's Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow's commercial business, focusing on the day-to-day management of Harrow's market‑leading compounded division. DiPasquale

      5/13/24 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance

      Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance, responsible for overseeing and managing all regulatory related submissions and strategy related to the Company's portfolio of new and existing products. Dr. Mannebach's successful 30-year career in the pharmaceutical industry, much of which was focused in ophthalmology, includes leadership roles in regulatory affairs, quality assurance, program management and pharmaceutical product development. "Dr. Mannebach brings to Harrow decades of regulatory and clinical expertise and leadership –specifically in ophth

      3/6/23 8:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Harrow with a new price target

      H.C. Wainwright initiated coverage of Harrow with a rating of Buy and set a new price target of $57.00

      2/6/25 7:06:49 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities reiterated coverage on Harrow with a new price target

      B. Riley Securities reiterated coverage of Harrow with a rating of Buy and set a new price target of $69.00 from $73.00 previously

      12/4/24 8:02:39 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum initiated coverage on Harrow with a new price target

      Craig Hallum initiated coverage of Harrow with a rating of Buy and set a new price target of $24.00

      4/11/24 7:51:28 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $HROW
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Large owner Opaleye Management Inc. sold $144,024 worth of shares (4,796 units at $30.03) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      6/5/25 4:05:47 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Opaleye Management Inc. sold $391,904 worth of shares (15,000 units at $26.13) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      5/14/25 4:56:15 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Large owner Opaleye Management Inc. sold $148,200 worth of shares (5,000 units at $29.64) (SEC Form 4)

      4/A - HARROW, INC. (0001360214) (Issuer)

      5/14/25 4:54:55 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow to Present at Two Investor Conferences in May

      Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May: B. Riley Securities 25th Annual Investor Conference (The Ritz-Carlton, Marina del Rey, CA) Format: Fireside Chat, followed by 1x1 Investor Meetings Date/Time: Wednesday, May 21, 2025, through Thursday, May 22, 2025 Craig-Hallum 22nd Annual Institutional Investor Conference (Depot Renaissance Hotel, Minneapolis, MN) Format: 1x1 and Small Group Investor Meetings Date/Time: Wednesday, May 28, 2025 Investors interested in meeting with management during either conference should contact their B. Riley or Craig-Hallum r

      5/14/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Announces First-Quarter 2025 Financial Results

      First-Quarter 2025 and Recent Selected Highlights: Revenues of $47.8 million, a 38% increase over $34.6 million recorded in prior-year period VEVYE revenues increased to $21.5 million, a 35% increase from $16.0 million in the fourth quarter 2024 Cash flow from operations reached a record high of $19.7 million GAAP net loss of $(17.8) million Adjusted EBITDA of $(2.0) million Cash and cash equivalents of $66.7 million as of March 31, 2025 VEVYE® Access for All launch in mid-March is accelerating market share capture and revenue growth Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2025. Th

      5/8/25 4:01:00 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

      Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on May 9, 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Friday, May 9, 2025, to discuss the results and provide a business update. Conference Call Information Participants can access the live conference call via webcast on th

      5/5/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    SEC Filings

    See more
    • SEC Form 10-Q filed by Harrow Inc.

      10-Q - HARROW, INC. (0001360214) (Filer)

      5/8/25 4:16:04 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HARROW, INC. (0001360214) (Filer)

      5/8/25 4:05:12 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Harrow Inc.

      DEFA14A - HARROW, INC. (0001360214) (Filer)

      4/25/25 8:01:18 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Harrow Inc.

      SC 13G/A - HARROW, INC. (0001360214) (Subject)

      12/5/24 7:08:52 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Harrow Inc.

      SC 13G/A - HARROW, INC. (0001360214) (Subject)

      10/8/24 6:41:41 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Harrow Inc. (Amendment)

      SC 13G/A - HARROW, INC. (0001360214) (Subject)

      2/13/24 5:25:53 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Financials

    Live finance-specific insights

    See more

    $HROW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Harrow Announces First-Quarter 2025 Financial Results

      First-Quarter 2025 and Recent Selected Highlights: Revenues of $47.8 million, a 38% increase over $34.6 million recorded in prior-year period VEVYE revenues increased to $21.5 million, a 35% increase from $16.0 million in the fourth quarter 2024 Cash flow from operations reached a record high of $19.7 million GAAP net loss of $(17.8) million Adjusted EBITDA of $(2.0) million Cash and cash equivalents of $66.7 million as of March 31, 2025 VEVYE® Access for All launch in mid-March is accelerating market share capture and revenue growth Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2025. Th

      5/8/25 4:01:00 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

      Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on May 9, 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Friday, May 9, 2025, to discuss the results and provide a business update. Conference Call Information Participants can access the live conference call via webcast on th

      5/5/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

      Fourth-Quarter, Full-Year 2024, and Recent Highlights: Record revenues of $66.8 million for Q4 2024, an 84% increase over Q4 2023 Revenues of $199.6 million for FY 2024, a 53% increase over FY 2023 GAAP net income of $6.8 million for Q4 2024, for a GAAP net loss of $(17.5) million for FY 2024 Adjusted EBITDA of $22.5 million for Q4 2024, leading to Adjusted EBITDA of $40.3 million for FY 2024 IHEEZO® unit demand and VEVYE® prescriptions for Q4 2024 each increased over 40% over Q3 2024 VEVYE® Access for All program expected to drive continued market share expansion in 2025 TRIESENCE® transitional pass-through approved, significantly increasing addressable market opportunity H

      3/27/25 4:01:00 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Opaleye Management Inc. bought $199,400 worth of shares (20,000 units at $9.97) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      4/25/24 5:19:24 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Opaleye Management Inc. bought $204,640 worth of shares (20,000 units at $10.23) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      4/24/24 4:40:20 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Opaleye Management Inc. bought $310,390 worth of shares (29,400 units at $10.56) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      4/19/24 6:24:32 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care